中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

106 records (took 0.016 seconds)

    EVALUATION OF POLYNOMIALS OVER FINITE FIELDS AND DECODING OF CYCLIC TOOLS
    62.
    发明申请
    EVALUATION OF POLYNOMIALS OVER FINITE FIELDS AND DECODING OF CYCLIC TOOLS 审中-公开
    有限域上多项式的估计和循环工具的解码

    公开(公告)号：WO2012098157A3

    公开(公告)日：2012-12-27

    申请号：PCT/EP2012050704

    申请日：2012-01-18

    Applicant: UNIV ZUERICH ,  ELIA MICHELE ,  ROSENTHAL JOACHIM JAKOB ,  SCHIPANI DAVIDE MOSE

    Inventor： ELIA MICHELE ,  ROSENTHAL JOACHIM JAKOB ,  SCHIPANI DAVIDE MOSE

    IPC: G06F17/10 ,  G06F7/72 ,  H03M13/15

    CPC classification number: H03M13/157 ,  G06F7/724 ,  G06F17/10 ,  H03M13/154 ,  H03M13/1545 ,  H03M13/158

    Abstract: An apparatus and method are disclosed for evaluating an input polynomial (p(x)) in a (possibly trivial) extension of the finite field of its coefficients, which are useful in applications such as syndrome evaluation in the decoding of cyclic codes. The apparatus comprises a decomposition/evaluation module (110) configured to iteratively decompose the input polynomial into sums of powers of the variable x, multiplied by powers of transformed polynomials, wherein each transformed polynomial has a reduced degree as compared to the input polynomial, and to evaluate the decomposed input polynomial. In another aspect, an apparatus and method of identifying errors in a data string based in a cyclic code are disclosed, which employ the Cantor-Zassenhaus algorithm for finding the roots of the error-locator polynomial, and which employ Shank's algorithm for computing the error locations from these roots.

    Abstract translation: 公开了一种用于评估其系数的有限域的（可能不重要的）扩展中的输入多项式（p（x））的装置和方法，其可用于诸如循环码解码中的症候群评估等应用中。 该装置包括分解/评估模块（110），其被配置为迭代地将输入多项式分解为变量x的幂乘以变换多项式的幂，其中每个变换多项式与输入多项式相比具有减小的程度，以及 评估分解的输入多项式。 另一方面，公开了一种识别基于循环码的数据串中的错误的设备和方法，其使用Cantor-Zassenhaus算法来找出错误定位器多项式的根，并且使用Shank's算法来计算错误 来自这些根源的位置。

    METAL COMPLEXES
    64.
    发明申请
    METAL COMPLEXES 审中-公开
    金属复合材料

    公开(公告)号：WO2009112823A8

    公开(公告)日：2011-01-13

    申请号：PCT/GB2009000650

    申请日：2009-03-10

    Applicant: UNIV ZUERICH ,  ALBERTO ROGER ,  BRABAND HENRIK ,  JONES NICHOLAS ANDREW

    Inventor： ALBERTO ROGER ,  BRABAND HENRIK

    IPC: C07F13/00 ,  A61K51/00

    CPC classification number: A61K51/0482 ,  C07F13/005

    Abstract: A method for synthesizing a complex having the formula: [L3MO3]" wherein L3 represents a tridentate ligand, M represents a metal selected from Tc an Re, and n is a charge from -2 to +1, the method comprising: a) reaction of pertechnetate or perrhenate with a reducing agent and L3, or b) reaction of pertechnetate or perrhenate with a Lewis acid and L3, wherein the synthesis (a) or (b) is carried out in an aqueous medium.

    Abstract translation: 一种合成具有下式的络合物的方法：其中L3表示三齿配体，M表示选自Tc-Re的金属，n为-2至+1的电荷，该方法包括：a）反应 的高锝酸盐或高铼酸盐与还原剂和L3反应，或b）高锝酸盐或高铼酸盐与路易斯酸和L3的反应，其中合成（a）或（b）在水性介质中进行。

    TREATMENT OF SCLERODERMA
    65.
    发明申请
    TREATMENT OF SCLERODERMA 审中-公开
    治疗SCLERODERMA

    公开(公告)号：WO2010026213A3

    公开(公告)日：2010-05-27

    申请号：PCT/EP2009061454

    申请日：2009-09-04

    Applicant: UNIV ZUERICH PROREKTORAT MNW ,  GAY STEFFEN ,  DISTLER OLIVER ,  MAURER BRITTA

    Inventor： GAY STEFFEN ,  DISTLER OLIVER ,  MAURER BRITTA

    IPC: A61K31/713

    CPC classification number: A61K31/713

    Abstract: The present invention provides a method of treating scleroderma. The method consists in the upregulation of miR-29 by administration of miR-29 or a miR-29 upregulator which elevates circulating and/or intracellular concentrations of miR-29. The invention likewise relates to the use of miR-29 for such a treatment, and the use of miR-29 for the manufacture of a medicament for the treatment of scleroderma.

    Abstract translation: 本发明提供一种治疗硬皮病的方法。 该方法包括通过施用提高miR-29的循环和/或细胞内浓度的miR-29或miR-29上调来上调miR-29。 本发明同样涉及miR-29用于这种治疗的用途，以及miR-29在制备用于治疗硬皮病的药物中的用途。

    POLYMORPHIC FORMS OF OLOPATADINE HYDROCHLORIDE AND METHODS FOR PRODUCING OLOPATADINE AND SALTS THEREOF
    68.
    发明申请
    POLYMORPHIC FORMS OF OLOPATADINE HYDROCHLORIDE AND METHODS FOR PRODUCING OLOPATADINE AND SALTS THEREOF 审中-公开
    奥伐他汀氢氯化物的多晶型及其制备方法及其制备方法

    公开(公告)号：WO2007110761A8

    公开(公告)日：2007-12-27

    申请号：PCT/IB2007000793

    申请日：2007-03-23

    Applicant: UNIV ZUERICH ,  AZAD PHARMACEUTICAL INGREDIENT

    Inventor： BADER THOMAS ,  BICHSEL HANS-ULRICH ,  GILOMEN BRUNO ,  MEYER-WILMES IMELDA ,  SUNDERMEIER MARK

    IPC: C07D313/12 ,  A61K31/335 ,  A61P37/00 ,  C07F9/54

    CPC classification number: C07F9/5325 ,  C07D313/12 ,  C07F9/5352 ,  C07F9/5442

    Abstract: The invention concerns a process for preparing olopatadine or a salt thereof, comprising:. (a) reacting 11-oxo-6,11-dihydroxydibenz[b,e]oxepin-2-acetic acid, a Wittig reagent selected from the group consisting of 3-dimethylamino-propyltriphenylphosphonium halides and salts thereof, and a suitable base, under Wittig reaction conditions, to provide a reaction mixture containing olopatadine; (b) adding an amount of water sufficient to protonate residual ylide present in the reaction mixture to provide a hydrolyzed reaction mixture; (c) adjusting, if necessary, the pH of the hydrolyzed reaction mixture, or aqueous phase thereof, to a pH of about pH 12 or higher to convert excess 3-dimethylamino- propyltriphenylphosphonium halide, or salt thereof, into 3-dimethylamino- propyldiphenylphosphine oxide; (d) extracting the solution of step (c) with a suitable solvent to provide a solution containing a diastereomeric mixture of olopatadine and (E)-11 -[3-dimethylaminopropylidene]- 6,1 l-dihydrodibenz[b,e]oxepin-2-acetic acid and having a substantially reduced amount of 3- dimethylamino-propyldiphenylphosphine oxide; (e) adjusting the pH of the solution obtained in step (d) to a pH between pH 4 and pH 5 to provide acid-addition salts of olopatadine and (E)-11-[3-dimethylaminopropylidene]- 6,1 l-dihydrodibenz[b,e]oxepin-2-acetic acid; (f) extracting the acid-addition salts of olopatadine and (E)-11-[3- dimethylaminopropylidene]-6,l l-dihydrodibenz[b,e]oxepin-2-acetic with a water-miscible solvent selected from the group consisting of (i) n-butanol; and (ii) mixtures of methyl-THF and a C1-C4 alcohol; provided that if the selected solvent is a mixture of methyl-THF and a Cl - C4 alcohol, then the solution is evaporated and the residue is taken up in n-butanol/water; (g) concentrating by azeotropic distillation the n-butanol/water solvent containing the acid-addition salts of olopatadine and (E)-11-[3-dimethylaminopropylidene]-6,11- dihydrodibenz[b,e]oxepin-2-acetic acid; and (h) fractionnally crystallizing the acid-addition salt of olopatadine.

    Abstract translation: 本发明涉及一种制备奥洛他定或其盐的方法，包括： （a）使11-氧代-6,11-二羟基二苯并[b，e]氧杂七环素-2-乙酸，选自3-二甲基氨基 - 丙基三苯基鏻卤化物及其盐的Wittig试剂和合适的碱， 维蒂希反应条件，提供含奥洛他定的反应混合物; （b）加入一定量的足以使存在于反应混合物中的残留叶立德质子化的水以提供水解的反应混合物; （c）如果需要，将水解的反应混合物或其水相的pH调节至约pH 12或更高的pH以将过量的3-二甲基氨基 - 丙基三苯基鏻卤化物或其盐转化为3-二甲基氨基 - 丙基二苯基膦 氧化物; （d）用合适的溶剂提取步骤（c）的溶液，以提供含有奥洛他定与（E）-11- [3-二甲氨基亚丙基] -6,11-二氢二苯并[b，e]氧杂七环素的非对映体混合物的溶液 -2-乙酸，并且具有显着减少量的3-二甲基氨基 - 丙基二苯基氧化膦; （e）将步骤（d）中获得的溶液的pH调节至pH4和pH5之间的pH，以提供奥洛他定和（E）-11- [3-二甲基氨基亚丙基] -6,1,1-三氟乙酸的酸加成盐， 二氢二苯并[b，e]氧杂七环素-2-乙酸; （f）用选自下组的水混溶性溶剂萃取奥洛他定和（E）-11- [3-二甲基氨基亚丙基] -6,11-二氢二苯并[b，e]氧杂七环素-2-乙酸的酸加成盐 由（i）正丁醇组成; 和（ii）甲基-THF和C1-C4醇的混合物; 条件是如果所选择的溶剂是甲基-THF和C1-C4醇的混合物，则将溶液蒸发并将残余物溶于正丁醇/水中; （g）通过共沸蒸馏浓缩含有奥洛他定和（E）-11- [3-二甲基氨基亚丙基] -6,11-二氢二苯并[b，e]氧杂七环素-2-乙酸的酸加成盐的正丁醇/水溶剂 酸; 和（h）将奥洛他定的酸加成盐分级结晶。

    POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF TRANDOLAPRILAT, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCTION AND USE
    69.
    发明申请
    POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF TRANDOLAPRILAT, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCTION AND USE 审中-公开
    三萜皂甙，药物组合物的多晶型和假多晶型以及生产和使用方法

    公开(公告)号：WO2007113680A3

    公开(公告)日：2007-12-06

    申请号：PCT/IB2007001027

    申请日：2007-04-04

    Applicant: AZAD PHARMACEUTICAL INGREDIENT ,  UNIV ZUERICH

    Inventor： BADER THOMAS

    IPC: C07D209/42 ,  A61K31/404 ,  A61P9/12

    CPC classification number: C07D209/42

    Abstract: The present invention provides novel polymorphic and pseudopolymorphic forms of Trandolaprilat, including crystalline Trandolaprilat Form A, crystalline Trandolaprilat Form B, crystalline Trandolaprilat Form C, crystalline Trandolaprilat Form D, crystalline Trandolaprilat Form E, and mixtures thereof. The invention also provides novel methods for producing Trandolaprilat, pharmaceutically acceptable salts of Trandolaprilat, and polymorphic and pseudopolymorphic forms of Trandolaprilat, pharmaceutical compositions including one or more novel Trandolaprilat compounds and methods for treating high blood pressure and/or cardiac insufficiency using one or more novel Trandolaprilat compounds.

    Abstract translation: 本发明提供了新的多晶型和假多晶型，包括结晶型Trandolaprilat A型，结晶型Trandolaprilat B型，结晶型Trandolaprilat C型，结晶型Trandolaprilat D型，结晶型Trandolaprilat型E及其混合物。 本发明还提供了用于生产Trandolaprilat，Trandolaprilat的药学上可接受的盐以及Trandolaprilat的多晶型和假多晶型形式的新颖方法，包含一种或多种新Trandolaprilat化合物的药物组合物以及使用一种或多种新型药物治疗高血压和/或心功能不全的方法 Trandolaprilat化合物。

    USE OF METAL TRICARBONYL COMPLEXES AS RADIOTHERAPEUTIC CHEMOTOXIC AGENTS
    70.
    发明申请
    USE OF METAL TRICARBONYL COMPLEXES AS RADIOTHERAPEUTIC CHEMOTOXIC AGENTS 审中-公开
    金属三羰基复合物作为放射治疗药物代谢物的使用

    公开(公告)号：WO2005039648A2

    公开(公告)日：2005-05-06

    申请号：PCT/EP2004011953

    申请日：2004-10-20

    Applicant: UNIV ZUERICH ,  ALBERTO ROGER ,  ZOBI FABIO

    Inventor： ALBERTO ROGER ,  ZOBI FABIO

    IPC: A61K33/24 ,  A61K51/04 ,  A61K51/08 ,  A61P35/00

    CPC classification number: A61K51/0476 ,  A61K33/24 ,  A61K51/0478

    Abstract: The invention relates to the use of metal tricarbonyl compounds of the general formula [M(CO),L,]', wherein M is rhenium or technetium or an isotope thereof and L is a ligand, for the preparation of a medicament for the treatment of cancer that is both radiotherapeutic and chemotoxic when a radioactive metal is used and chemotoxic when cold rhenium or macroscopic amounts of long-lived Tc-99 is used. The medicament is in particular chemotoxic by causing intrastrand linkages in DNA. In a specific embodiment at least one of L is not OH2. The invention further relates to novel compounds of the general formula IM(CO)3XIX2X3]+and their use, wherein M is rhenium or technetium or an isotope thereof and at least one of X1. X2 and X3 is a monodentate ligand; or two of X, X2 and X3 are part of a bidentate ligand and the other one is optionally a monodentate ligand.

    Abstract translation: 本发明涉及通式[M（CO），L，]'的金属三羰基化合物的用途，其中M是铼或锝或其同位素，L是配体，用于制备治疗药物 当放射性金属被使用时既放射治疗又具有化学毒性，并且当使用冷铼或宏观量的长寿命Tc-99时具有化学毒性。 该药物特别是通过在DNA中引起链内连锁的化学毒性。 在具体实施方案中，L中的至少一个不是OH 2。 本发明还涉及通式为IM（CO）3 XIX 2 X 3] +的新化合物及其用途，其中M为铼或锝或其同位素和X1中的至少一种。 X2和X3是单齿配体; X，X 2和X 3中的两个是二齿配体的一部分，另一个是任选的单齿配体。

Patent Agency Ranking